Does Wegovy cause UTI symptoms, or is something else going on?

What the STEP 1 trial data and Wegovy's prescribing information record

The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults and tracked adverse events systematically over 68 weeks at the 2.4 mg maintenance dose. The side-effect profile that emerged was predominantly gastrointestinal: nausea affected roughly 44% of participants, diarrhoea around 30%, vomiting around 24%, and constipation around 24%. These reactions clustered around dose escalation periods and typically eased within a fortnight.

Urinary tract infections did not feature in the common or uncommon adverse-reaction tables. The NHS semaglutide medicines page mirrors this: the listed side effects cover GI symptoms, headache, fatigue, dizziness and injection-site reactions. UTIs are absent. That absence matters, because clinical-trial safety monitoring is exhaustive. If UTIs were occurring at a meaningful rate, they would surface in the data.

This does not mean every symptom a person notices on Wegovy is unrelated to the medicine. It means that urinary discomfort has no established causal link to semaglutide itself. The more likely explanations are indirect, and they are worth understanding.

Why dehydration on Wegovy can produce symptoms people confuse with a UTI

Here is where the GI profile becomes relevant to your question. Nausea, vomiting and diarrhoea all reduce fluid intake or accelerate fluid loss. Many people on Wegovy find their appetite drops so sharply in the early weeks that they are eating and drinking far less than usual, sometimes forgetting to drink water between meals because hunger is no longer prompting them to the kitchen.

When fluid intake falls, urine becomes more concentrated. Concentrated urine can cause a burning sensation, urinary frequency and a feeling of pressure in the lower abdomen: symptoms that overlap almost exactly with a classic UTI presentation. The distinction matters because the management is completely different. Dehydration-related discomfort typically resolves quickly with increased water intake; a genuine bacterial infection requires antibiotics.

People starting Wegovy should actively monitor their fluid intake, particularly during dose-increase weeks when GI side effects tend to peak. If you are struggling to drink enough because nausea is severe, that is itself a symptom worth raising with your prescriber. Our guide to Wegovy side effects covers the GI profile in more detail, including practical steps for managing nausea in the early weeks.

When urinary symptoms during Wegovy treatment need medical attention

There is a practical difference between discomfort you can trace to poor hydration and symptoms that persist despite drinking more fluid, recur repeatedly, or arrive alongside fever, back or flank pain, or blood in the urine. The latter pattern suggests a genuine infection, or occasionally a kidney problem, and needs assessment the same day, not a wait-and-see approach.

People managing type 2 diabetes on semaglutide have an additional reason to take urinary symptoms seriously: elevated blood glucose can itself increase susceptibility to UTIs and other infections. If you have diabetes and are experiencing recurrent urinary symptoms, your prescriber needs to know.

For the majority of Wegovy users without diabetes, a UTI that coincides with starting treatment is almost certainly coincidental rather than caused by the medicine. But coincidental does not mean ignorable. You can report any suspected side effects, including ones you are unsure about, through the MHRA Yellow Card scheme, which exists precisely to track patterns that may not yet appear in prescribing information.

If you are weighing up Wegovy as a treatment option and want to understand how the full side-effect profile fits your personal health picture, the free consultation at nume connects you with a GPhC-registered prescriber who reviews your information the same day. There is no algorithm involved. A clinician reads your answers and decides whether treatment is appropriate for you. You can also explore how Wegovy compares with other licensed options on our weight-loss treatment overview.

Putting the risk in perspective: what Wegovy's known side-effect picture actually looks like

Understanding what Wegovy does as a weight-loss medicine and does not commonly cause helps you monitor yourself more accurately during treatment. The evidence-based list is dominated by GI effects, most of which are dose-dependent and temporary. Headache and fatigue appear less often. Injection-site reactions are minor and infrequent for most people.

Rarer but more serious events worth knowing include acute pancreatitis, which the MHRA flagged in a safety communication in January 2026: severe, persistent stomach pain that may spread to the back is a signal to get urgent medical help rather than manage at home. Gallbladder disease is also recognised at a low frequency in longer-term use.

UTIs are not on that list. If you started Wegovy recently and are reading this because you are experiencing urinary discomfort, the honest clinical answer is: stay well hydrated, give it 24–48 hours, and contact your GP or prescriber if symptoms persist, worsen, or arrive alongside fever, as these patterns need prompt attention rather than a wait-and-see approach. Our guide to semaglutide symptoms in the early days explains what to expect in the first week of treatment, which is when most people feel the adjustment most acutely.

For broader context on Wegovy as a treatment, including how the titration schedule works and what clinical assessment involves, our page covering what the symptoms of Wegovy look like across the treatment period is a useful starting point alongside the Wegovy overview page.